Form 4: OnKure Therapeutics CFO Sells Shares for Tax Obligations
Insider Transaction Report
OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, sold 303 shares of Class A Common Stock on June 23, 2025, at a weighted average price of $2.3842 to cover tax withholding obligations related to RSU vesting.
Summary
- Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics, Inc. (OKUR), reported a sale of company stock.
- The transaction occurred on June 23, 2025.
- A total of 303 shares of Class A Common Stock were sold.
- The weighted average sale price for the shares was $2.3842.
- The sale was an automatic transaction executed to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
- This transaction was conducted pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
- Following the reported transaction, Mr. Leverone beneficially owns 12,906 shares of Class A Common Stock, which includes certain RSUs.
Sentiment
Score: 5
Explanation: The transaction is a routine sale of shares by an executive to cover tax obligations upon RSU vesting, which is a common and expected event and does not indicate a change in sentiment towards the company.
Future Outlook
The document, an SEC Form 4, reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- "These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ('RSUs'), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."
Industry Context
This Form 4 filing details a routine insider stock transaction, specifically a sale to cover tax obligations arising from RSU vesting. Such transactions are common across industries for executives receiving equity compensation and do not typically reflect broader industry trends or competitive positioning.
Key Dates
| Date | Description |
|---|---|
| 06/23/2025 | Date of transaction (sale of Class A Common Stock by Jason A. Leverone). |
| 06/25/2025 | Date the Form 4 was signed by Rogan Nunn, by power of attorney. |
Keywords
OnKure Therapeutics, OKUR, Form 4, insider transaction, stock sale, restricted stock units, RSU, tax withholding, executive compensation, Jason A. Leverone, Chief Financial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.